Category

Archives

FGFR

Paeoniflorin exerts antidepressant-like effects through enhancing neuronal FGF-2 by microglial inactivation

3 views | Apr 23 2021

Jie Cheng et al. found that paeoniflorin exhibited neuroprotective and antidepressant effects in mice, which might be mediated by activating neuronal FGF-2/FGFR1 signaling via the inhibition of microglial activation in the hippocampus. [Read the Full Post]

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma

5 views | Apr 02 2021

Robert Hanes et al. supported LY2874455 as a better therapy than NVP-BGJ398 for FRS2-amplified liposarcoma, and a clinical trial was warranted. [Read the Full Post]

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma

9 views | Mar 22 2021

Lipika Goyal et al. demonstrated that the irreversible FGFR inhibitor TAS-120 provided clinical benefit in patients with resistance to BGJ398 or Debio 1347 and overcomed several FGFR2 mutations in ICC models. [Read the Full Post]

A Three-Dimensional Organoid Culture Model to Assess the Influence of Chemicals on Morphogenetic Fusion

6 views | Mar 22 2021

David G Belair et al. demonstrated the utility of the in vitro fusion assay for identifying chemicals that disrupted human organoid morphogenesis in a scalable format amenable to toxicology screening. [Read the Full Post]

Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma

11 views | Mar 03 2021

M -L Nairismägi found that the activity of PRN371 had a more durable inhibition on JAK3 compared to tofacitinib in vitro, leading to significant tumor growth inhibition in a NKTL xenograft model harboring JAK3 activating mutation. [Read the Full Post]

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial

12 views | Feb 19 2021

C Dinkic et al. thought that Pazopanib 600mg daily p.o. and metronomic cyclophosphamide 50mg daily p.o. was a feasible regimen for patients with recurrent platinum-resistant EOC and showed promising activity in this previously treated patient population. [Read the Full Post]

Kanglexin accelerates diabetic wound healing by promoting angiogenesis via FGFR1/ERK signaling

19 views | Jan 15 2021

Yixiu Zhao et al. thought that KLX had the potential to be developed as a topical drug to promote diabetic wound healing. [Read the Full Post]

Advances on Synthesis, Derivatization and Bioactivity of Isatin: A Review

58 views | Sep 28 2020

Garima Chauhan et al. reviewed the different strategies for the designs and synthesis of several IST based compounds having different biological activities with SAR which could favour further investigation and modification for the development of new and more potent entities. [Read the Full Post]

FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential

43 views | Sep 19 2020

Jinglin Zhang et al. highlighted the translational potential of FGFR2-c-Jun-YAP1 axis, which might serve as a prognostic biomarker and therapeutic target for GC. [Read the Full Post]

Inhibition of FGFR Signaling Partially Rescues Osteoarthritis in Mice Overexpressing High Molecular Weight FGF2 Isoforms

68 views | Aug 05 2020

Liping Xiao et al. demonstrated that overexpression of the HMWFGF2 isoforms in preosteoblasts resulted in osteoarthropathy that couid be partially rescued by FGFR inhibitor via reduction in activated Wnt signaling. [Read the Full Post]